J Korean Med Sci.  1998 Dec;13(6):612-616. 10.3346/jkms.1998.13.6.612.

Combination chemotherapy of oral 5'-deoxy-5-fluorouridine and cisplatin in advanced gastric cancer: a phase II study

• Ahn MJ
• Han DS
• Sohn JH
• Jeon YC
• Jun DW
• Choi NW
• Park HK
• Baik HK
• Lee HG
• Nam YS
• Choi IY

• KMID: 1038441
• DOI: http://doi.org/10.3346/jkms.1998.13.6.612

Abstract

This study was designed to test the activity and feasibility of 5'-deoxy-5-fluorouridine (5'-DFUR) and cisplatin combination therapy in the treatment of advanced gastric cancer. Nineteen patients with inoperable and/or metastatic gastric cancer, which was histologically proven, were orally administered 5'-DFUR 1,200 mg/m2 on days 1 to 4 and days 15-18 combined with 70 mg/m2 of cisplatin being repeated every 4 weeks. Five partial responses (PRs) were achieved. Seven patients had stable disease and 6 progressed on therapy. The overall response rate was 27.7% (95% confidence interval: 9.69% to 53.5%). The median survival duration of all 18 patients was 25 weeks (9-64). The majority of patients had WHO grade I/II toxicity, but there was no treatment-related death. These data support that the combinations of oral 5'-DFUR and cisplatin are well tolerable and have a moderate activity with low toxicity in the treatment of advanced gastric cancer.

MeSH Terms

Administration, Oral
Adult
Aged
Antineoplastic Agents, Combined/therapeutic use*
Antineoplastic Agents, Combined/adverse effects
Cisplatin/administration & dosage
Drug Administration Schedule
Female
Floxuridine/administration & dosage
Human
Infusions, Intravenous
Male
Middle Age
Stomach Neoplasms/drug therapy*